- Home
- TDC vs MESO Comparison
TDC vs MESO Comparison
Compare TDC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TDC | MESO |
|---|---|---|
| Founded | 1979 | 2004 |
| Country | United States | Australia |
| Employees | N/A | 81 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | TDC | MESO |
|---|---|---|
| Price | $30.21 | $15.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $34.78 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 185.4K |
| Earning Date | 05-05-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.38 | N/A |
| EPS | ★ 1.35 | N/A |
| Revenue | ★ $2,156,000,000.00 | N/A |
| Revenue This Year | $0.30 | $629.74 |
| Revenue Next Year | $1.44 | $30.65 |
| P/E Ratio | $21.69 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.83 | $9.88 |
| 52 Week High | $41.78 | $21.50 |
Technical Indicators
Market Signals| Indicator | TDC | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 68.74 | 52.96 |
| Support Level | $28.98 | $15.62 |
| Resistance Level | $32.03 | $16.37 |
| Average True Range (ATR) | 1.09 | 0.38 |
| MACD | 0.43 | 0.03 |
| Stochastic Oscillator | 92.47 | 34.92 |
Price Performance
Historical ComparisonAbout TDC Teradata Corporation
Teradata Corp focused on helping organizations improve business performance, enrich customer experiences, and integrate data across the enterprise. The company's platform provides companies with Harmonized Data: Trusted AI: Teradata VantageCloud: Teradata VantageCore: ClearScape Analytics: and Query Grid. The company generates majority of revenue from the United States.
About MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.